A RANDOMIZED PHASE 3 TRIAL OF TRC105 AND PAZOPANIB VERSUS PAZOPANIB ALONE IN PATIENTS WITH ADVANCED ANGIOSARCOMA (TAPPAS)
Phase of Trial: Phase III
Latest Information Update: 02 Dec 2017
At a glance
- Drugs Carotuximab (Primary) ; Pazopanib
- Indications Haemangiosarcoma
- Focus Registrational; Therapeutic Use
- Acronyms TAPPAS
- Sponsors TRACON Pharmaceuticals
- 07 Nov 2017 According to a TRACON Pharmaceuticals media release, Currently, more than 20 sites are open for accrual in the U.S., and sites in EU countries are expected to be open by the end of 2017.
- 08 Aug 2017 According to a TRACON Pharmaceuticals media release, the study continues to enroll well, and is on track to deliver key interim data in mid-2018.
- 06 Jun 2017 According to trial design presented at the 53rd Annual Meeting of the American Society of Clinical Oncology, an interim analysis is planned to occur upon the occurrence of 40 events in approximately 70 patients.